Remove Layoffs Remove Study Remove Technical Review Remove Technology
article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. —The 2016 Nobel Prize for Physiology or Medicine went to Yoshinori Ohsumi of the Tokyo Institute of Technology.

article thumbnail

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. All eyes are on Holmes, who is scheduled to present data from the company’s technology at a medical conference on August 1. Sarepta’s drug is currently under an FDA review.

News 40